Coenzyme
Q10 Definition Coenzyme
Q10 (CoQ 10) or ubiquinone is essentially a vitamin or vitamin-like substance.
Disagreements on nomenclature notwithstanding, vitamins are defined as organic
compounds essential in minute amounts for normal body function acting as coenzymes
or precursors to coenzymes. They are present naturally in foods and sometimes
are also synthesized in the body. CoQ10 likewise is found in small amounts in
a wide variety of foods and is synthesized in all tissues. The biosynthesis of
CoQ10 from the amino acid tyrosine is a multistage process requiring at least
eight vitamins and several trace elements. Coenzymes are cofactors upon which
the comparatively large and complex enzymes absolutely depend for their function.
Coenzyme Q10 is the coenzyme for at least three mitochondrial enzymes (complexes
I, II and III) as well as enzymes in other parts of the cell. Mitochondrial enzymes
of the oxidative phosphorylation pathway are essential for the production of the
high-energy phosphate, adenosine triphosphate (ATP), upon which all cellular functions
depend. The electron and proton transfer functions of the quinone ring are of
fundamental importance to all life forms; ubiquinone in the mitochondria of animals,
plastoquinone in the chloroplast of plants, and menaquinone in bacteria. The term
"bioenergetics" has been used to describe the field of biochemistry
looking specifically at cellular energy production. In the related field of free
radical chemistry, CoQ10 has been studied in its reduced form as a potent antioxidant.
Structure 
History
CoQ10
was first isolated from beef heart mitochondria by Dr. Frederick Crane of Wisconsin,
U.S.A., in 1957 (2). The same year, Professor Morton of England defined a compound
obtained from vitamin A deficient rat liver to be the same as CoQ10(3). Professor
Morton introduced the name ubiquinone, meaning the ubiquitous quinone. In 1958,
Professor Karl Folkers and coworkers at Merck, Inc., determined the precise chemical
structure of CoQ10: 2,3 dimethoxy-5 methyl-6 decaprenyl benzoquinone 1), synthesized
it, and were the first to produce it by fermentation. In the mid-1960's, Professor
Yamamura of Japan became the first in the world to use coenzyme Q7 (a related
compound) in the treatment of human disease: congestive heart failure. In 1966,
Mellors and Tappel showed that reduced CoQ6 was an effective antioxidant In 1972
Gian Paolo Littarru of Italy along with Professor Karl Folkers documented a deficiency
of CoQ10 in human heart disease By the mid-1970's, the Japanese perfected the
industrial technology to produce pure CoQ10 in quantities sufficient for larger
clinical trials. Peter Mitchell received the Nobel Prize in 1978 for his contribution
to the understanding of biological energy transfer through the formulation of
the chemiosmotic theory, which includes the vital protonmotive role of CoQ10 in
energy transfer systems
In the early 1980's, there was a considerable
acceleration in the number and size of clinical trials. These resulted in part
from the availability of pure CoQ10 in large quantities from pharmaceutical companies
in Japan and from the capacity to directly measure CoQ10 in blood and tissue by
high performance liquid chromatography. Lars Ernster of Sweden, enlarged upon
CoQ10's importance as an antioxidant and free radical scavenger Professor Karl
Folkers went on to receive the Priestly Medal from the American Chemical Society
in 1986 and the National Medal of Science from President Bush in 1990 for his
work with CoQ10 and other vitamins.
COENZYME
Q10 DEFICIENCY
Normal blood and tissue levels of CoQ10 have
been well established by numerous investigators around the world. Significantly
decreased levels of CoQ10 have been noted in a wide variety of diseases in both
animal and human studies. CoQ10 deficiency may be caused by insufficient dietary
CoQ10, impairment in CoQ10 biosynthesis, excessive utilization of CoQ10 by the
body, or any combination of the three. Decreased dietary intake is presumed in
chronic malnutrition and cachexia.
The relative contribution of CoQ10
biosynthesis versus dietary CoQ10 is under investigation. Karl Folkers takes the
position that the dominant source of CoQ10 in man is biosynthesis. This complex,
17 step process, requiring at least seven vitamins (vitamin B2 - riboflavin, vitamin
B3 - niacinamide, vitamin B6, folic acid, vitamin B12, vitamin C, and pantothenic
acid) and several trace elements, is, by its nature, highly vulnerable. Karl Folkers
argues that suboptimal nutrient intake in man is almost universal and that there
is subsequent secondary impairment in CoQ10 biosynthesis. This would mean that
average or "normal" levels of CoQ10 are really suboptimal and the very
low levels observed in advanced disease states represent only the tip of a deficiency
"ice berg".
HMG-CoA reductase inhibitors used to treat elevated
blood cholesterol levels by blocking cholesterol biosynthesis also block CoQ10
biosynthesisThe resulting lowering of blood CoQ10 level is due to the partially
shared biosynthetic pathway of CoQ10 and cholesterol. In patients with heart failure
this is more than a laboratory observation. It has a significant harmful effect
which can be negated by oral CoQ10 supplementation
Increased body consumption
of CoQ10 is the presumed cause of low blood CoQ10 levels seen in excessive exertion,
hyper metabolism, and acute shock states. It is likely that all three mechanisms
(insufficient dietary CoQ10, impaired CoQ10 biosynthesis, and excessive utilization
of CoQ10) are operable to varying degrees in most cases of observed CoQ10 deficiency.
Clinical Applications §
High blood pressure (hypertension) Preliminary research suggests that CoQ10
causes small decreases in blood pressure (systolic and possibly diastolic). Low
blood levels of CoQ10 have been found in people with hypertension, although it
is not clear if CoQ10 "deficiency" is a cause of high blood pressure.
It is not known what dose is safe or effective. CoQ10 is less commonly used to
treat hypertension than it is for other heart conditions such as congestive heart
failure. Well-designed long-term research is needed to strengthen this recommendation.
Alzheimer's
disease Promising preliminary evidence from human research suggests
that CoQ10 supplements may slow down, but not cure, dementia in people with Alzheimer's
disease. Additional well-designed studies are needed to confirm this result before
a firm recommendation can be made. Grade C
Angina
(chest pain from clogged heart arteries) Preliminary small human
studies suggest that CoQ10 may reduce angina and improve exercise tolerance in
people with clogged heart arteries. Better studies are needed before a firm recommendation
can be made.
Anthracycline
chemotherapy heart toxicity Anthracycline chemotherapy drugs, such
as doxorubicin (Adriamycin®), are commonly used to treat cancers such as breast
cancer or lymphoma. Heart damage (cardiomyopathy) is a major concern with the
use of anthracyclines, and CoQ10 has been suggested to protect the heart. However,
studies in this area are small and not high quality and the effects of CoQ10 remain
unclear.
Breast
cancer Several studies in women with breast cancer report reduced
levels of CoQ10 in diseased breast tissue or blood. It has been suggested by some
researchers that raising CoQ10 levels with supplements might be helpful. However,
it is not clear if CoQ10 is beneficial in these patients, or if the low levels
of CoQ10 may actually be a part of the body's natural response to cancer, helping
to fight disease. Supplementation with CoQ10 has not been proven to reduce cancer,
and has not been compared to other forms of treatment for breast cancer.
Cardiomyopathy
(dilated, hypertrophic)
There
is conflicting evidence from research on the use of CoQ10 in patients with dilated
or hypertrophic cardiomyopathy. Different levels of disease severity have been
studied (New York Heart Association heart failure classes I through IV). Some
studies report improved heart function (ejection fraction, stroke volume, cardiac
index, exercise tolerance), while others find no improvements. Most trials are
small or not well designed. Better research is needed in this area before a recommendation
can be made.
Exercise
performance The effects of CoQ10 on exercise performance have been
tested in athletes, normal healthy individuals, and in people with chronic lung
disease. Results are variable, with some research suggesting benefits, and other
studies showing no effects. Most trials have not been well-designed. Better research
is necessary before a firm conclusion can be drawn.
Friedreich's
ataxia Preliminary research reports promising evidence for the
use of CQ10 in the treatment of Friedreich's ataxia. Further evidence is necessary
before a firm conclusion can be drawn.
Gum
disease (periodontitis) Preliminary human studies suggest possible
benefits of CoQ10 taken by mouth or placed on the skin or gums in the treatment
of periodontitis. Improvements in bleeding, swelling, and pain are reported. However,
available studies are small and not high quality. Better research is needed before
a conclusion can be drawn.
Heart
attack (acute myocardial infarction) There is preliminary human
study of CoQ10 given to patients within three days after a heart attack. Reductions
in deaths, abnormal heart rhythms, and second heart attacks are reported, although
better research is needed before a firm conclusion can be drawn.
Heart
conditions (mitral valve prolapse in children) There is early data
to support the use of CoQ10 in children with mitral valve prolapse. Well-designed
clinical trials are needed before a recommendation can be made.
Heart
failure The evidence for CoQ10 in the treatment of heart failure
is controversial and remains unclear. Different levels of disease severity have
been studied (New York Heart Association classes I through IV). Several studies
have shown benefits of coenzyme Q10 in people who have been diagnosed with chronic
heart failure (with or without cardiomyopathy), including in transplant recipients.
Some studies report improved heart function (ejection fraction, stroke volume,
cardiac index, exercise tolerance), while others find no improvements. Most trials
are small or not well designed. In some parts of Europe, Russia, and Japan, CoQ10
is considered a part of standard therapy for congestive heart failure patients.
Better research is needed in this area, studying effects on quality of life, hospitalization,
death rates, before a recommendation can be made.
Heart
protection during surgery Several studies suggest that the function
of the heart may be improved after major heart surgeries such as coronary artery
bypass graft (CABG) or valve replacement when CoQ10 is given to patients before
or during surgery. Better studies that measure effects on long-term heart function
and survival are necessary before a recommendation can be made.
HIV/AIDS
There is limited evidence that natural levels of CoQ10 in the body
may be reduced in people with HIV/AIDS. There is no reliable scientific research
showing that CoQ10 supplements have any effect on this disease.
Increasing
sperm count (idiopathic spermatozoa) There
is early evidence that supports the use of CoQ10 in the treatment of increasing
sperm count and motility. Better studies are needed before a strong recommendation
can be made.
Kidney
failure There is initial data from one small trial to support the
use of CoQ10 in the treatment of kidney (renal) failure. More research is needed
before a recommendation can be made
Migraine
There is fair evidence to support the use of CoQ10 treatment in
migraine prevention or treatment. However, more well-designed studies are needed
to confirm these findings.
Mitochondrial
diseases and Kearns-Sayre syndrome COQ10 is often recommended for
patients with mitochondrial diseases, including myopathies, encephalomyopathies,
and Kearns-Sayre syndrome. Several early studies report improvements in metabolism
and physical endurance in patients with these conditions after treatment with
CoQ10, although most available research is not high quality or definitive. Better
studies are needed before a strong recommendation can be made.
Muscular
dystrophies Preliminary studies in patients with muscular dystrophy
taking COQ10 supplements describe improvements in exercise capacity, heart function,
and overall quality of life. Additional research is needed in this area.
Parkinson's
disease There is promising human evidence for the use of CoQ10
in the treatment of Parkinson's disease. Better-designed trials are needed to
confirm these results.
Diabetes
Preliminary evidence suggests that CoQ10 does not affect blood sugar levels
in patients with type 1 or type 2 diabetes, and does not alter the need for diabetes
medications.
Huntington's
disease There
is negative evidence from studies that used CoQ10 in the treatment of Huntington's
disease.
Standardization
Standardization involves measuring the amount of certain chemicals
in products to try to make different preparations similar to each other. It is
not always known if the chemicals being measured are the "active" ingredients.
CoQ10 products sold in stores have been found to contain variable amounts of claimed
ingredients. Early studies used low doses, while more recent research suggests
that higher doses may be safe and have greater effects.
- Adults
(18 years and older)
A) By mouth (oral)
:
General : 50-1200 milligrams
of CoQ10 have been taken in divided doses by mouth daily.
B)
On the skin (topical) :
Gum disease
(periodontitis) : 85 milligrams of CoQ10 per milliliter of soybean
oil suspension has been applied to the surface of affected areas once weekly using
a plastic syringe, in one study.
C. Through the
veins (intravenous) : Heart protection during surgery : Most studies
of CoQ10 for heart protection during bypass surgery have used CoQ10 taken by mouth.
One study used intravenous CoQ10, 5 milligrams per kilogram of body weight, given
2 hours prior to surgery. Safety is not clear. Any therapies used close to the
time of surgery should be discussed with the surgeon and a pharmacist prior to
starting.
-
Children (younger than 18 years)
There
is not enough scientific information to recommend the safe use of Coenzyme Q10
in children. A qualified healthcare provider should be consulted before considering
use.
Allergies
In theory, allergic reactions to supplements containing CoQ10 may
occur.
Side Effects and Warnings
There
are few serious reported side effects of CoQ10. Side effects are typically mild
and brief, stopping without any treatment needed. Reactions may include nausea,
vomiting, stomach upset, heartburn, diarrhea, loss of appetite, skin itching,
rash, insomnia, headache, dizziness, irritability, increased light sensitivity
of the eyes, fatigue, or flu-like symptoms.
CoQ10 may lower blood sugar
levels. Caution is advised in patients with diabetes or hypoglycemia, and in those
taking drugs, herbs, or supplements that affect blood sugar. Serum glucose levels
may need to be monitored by a healthcare provider, and medication adjustments
may be necessary.
Low blood platelet number was reported in one person
taking CoQ10. However, other factors (viral infection, other medications) may
have been responsible. Lowering of platelets may increase the risk of bruising
or bleeding, although there are no known reports of bleeding from CoQ10. Caution
is advised in people who have bleeding disorders or who are taking drugs that
increase the risk of bleeding. Dosing adjustments may be necessary.
CoQ10
may decrease blood pressure, and caution is advised in patients with low blood
pressure or taking blood pressure medications. Elevations of liver enzymes have
been reported rarely, and caution is advised in people with liver disease or taking
medications that may harm the liver. CoQ10 may lower blood levels of cholesterol
or triglycerides. Thyroid hormone levels may be altered based on one study.
Organ
damage due to lack of oxygen/blood flow during intense exercise has been reported
in a study of patients with heart disease, although the specific role of CoQ10
is not clear. Vigorous exercise is often discouraged in people using CoQ10 supplements.
|